Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Article Type
Date
Availability
1-3 of 3
Keywords: antithrombin III
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2017) 131 (9): 823–831.
Published: 19 April 2017
...Zeyuan Lu; Feng Wang; Mingyu Liang The gene SerpinC1 encodes a serine protease inhibitor named antithrombin III (ATIII). This protease demonstrates both anticoagulant and anti-inflammatory action. ATIII is the most important coagulation factor inhibitor, and even minor changes in ATIII can...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1981) 61 (3): 317–324.
Published: 01 September 1981
..., but had returned to the presupplementation value 5 weeks after withdrawal of the supplement. 5. The maximum estimated response to platelet aggregation induced by ADP was increased by the supplement. 6. The mean levels of antithrombin III (immunological) and blood pressure were lower at the end...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1981) 60 (6): 681–688.
Published: 01 June 1981
...Vivian Chan; C. L. Lai; T. K. Chan 1. The metabolism of human antithrombin III (ATIII) was studied by using 125 I-labelled tracer. 2. The plasma half-life ( t 0.5 ) was 2.71 ± 0.26 days in normal subjects and was similar in patients with cirrhosis or primary carcinoma of liver. 3. Patients...